Cochlear Ltd
Company Profile
Business description
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2026, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.
Contact
1 University Avenue
Macquarie University
SydneyNSW2109
AUST: +61 294286555
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
4,749
Cochlear Ltd News & Analysis
stocks
Reporting season was stronger than share prices suggest
markets
The grass is always greener: Rethinking Australian vs global equities
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,908.80 | 34.30 | 0.39% |
| CAC 40 | 8,140.59 | 50.31 | 0.62% |
| DAX 40 | 25,537.75 | 135.47 | 0.53% |
| Dow JONES (US) | 51,461.90 | 631.21 | -1.21% |
| FTSE 100 | 10,688.47 | 30.34 | 0.28% |
| HKSE | 24,476.28 | 237.50 | -0.96% |
| NASDAQ | 25,978.43 | 3.14 | -0.01% |
| Nikkei 225 | 63,966.87 | 43.87 | 0.07% |
| NZX 50 Index | 13,735.73 | 113.01 | 0.83% |
| S&P 500 | 7,551.81 | 33.92 | -0.45% |
| S&P/ASX 200 | 8,730.30 | 33.80 | 0.39% |
| SSE Composite Index | 3,880.85 | 10.75 | -0.28% |